| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8301146 | Biochimica et Biophysica Acta (BBA) - General Subjects | 2013 | 9 Pages |
Abstract
Association, conjugation or fusion of therapeutic drugs to albumin is a well-accepted and established half-life extension technology. The manipulation of the albumin-FcRn interaction will facilitate the modulation of the circulatory half-life of albumin-enabled drugs, leading to superior pharmacokinetics tailored to the disease state and increased patient compliance. This article is part of a Special Issue entitled Serum Albumin.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Darrell Sleep, Jason Cameron, Leslie R. Evans,